CDEK
← All drugs Report issue

linperlisib

Small moleculeexperimental

Clinical trial activity

33 trials · 19 clinical orgs · 0 marketing orgs

Phase 1
20
Phase 2
23
Phase 3
1
Phase 4
1

Earliest trial started Dec 25, 2017 (NCT03757000)

Timeline

2010s

  1. Jan 1, 2017

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2019

    Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

COc1ncc(-c2nc(N3CCOCC3)nc3c(CN4CCC(C(C)(C)O)CC4)cc(F)cc23)cc1NS(C)(=O)=O
Mol. weight
588.71 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07209163Phase 1/Phase 2 (Phase 2)Oct 31, 2025Jiao Tong University
NCT07139353Phase 1/Phase 2 (Phase 2)Sep 15, 2025Sun Yat-Sen University
NCT07031115Phase 2Sep 1, 2025Chinese Academy of Medical Sciences
NCT06981988Phase 1/Phase 2 (Phase 2)Jun 30, 2025Hengrui Therapeutics, Inc.
NCT06799676Phase 1/Phase 2 (Phase 2)Feb 28, 2025Xiamen University
NCT06793956Phase 1Feb 21, 2025Sun Yat-Sen University
NCT07195799Phase 2Dec 31, 2024Nanjing Medical University
NCT06712173Phase 1Dec 1, 2024China Academy of Chinese Medical Sciences
NCT06548347Phase 2/Phase 3 (Phase 3)Sep 10, 2024Shanghai YingLi Pharmaceutical Co. Ltd.
NCT06592170Phase 1/Phase 2 (Phase 2)Aug 13, 2024Jinlin University
NCT06489808Phase 2May 28, 2024China Academy of Chinese Medical Sciences, Chinese Academy of Medical Sciences
NCT06324994Phase 2May 1, 2024Dalian Medical University
NCT06343935Phase 4Apr 30, 2024Shanghai YingLi Pharmaceutical Co. Ltd.
NCT06376721Phase 1/Phase 2 (Phase 2)Apr 14, 2024Capital Medical University
NCT06421948Phase 1/Phase 2 (Phase 2)Jan 1, 2024Henan Medical University
NCT06224257Phase 2Dec 3, 2023China Academy of Chinese Medical Sciences, Shanghai YingLi Pharmaceutical Co. Ltd.
NCT06347653Phase 2Nov 28, 2023Peking University
NCT06158386Phase 2Nov 22, 2023Fujian Medical University, Fujian Provincial Hospital, Huizhou People's Central Hospital, Jieyang People's Hospital, Nanjing Medical University, Shanxi Medical University, Sun Yat-Sen University, Xiamen University
NCT06083701Phase 1/Phase 2 (Phase 2)Sep 25, 2023Chinese Academy of Medical Sciences
NCT05949944Phase 1/Phase 2 (Phase 2)Aug 15, 2023Sun Yat-Sen University
Showing 20 of 33 trials
Page 1 / 2

Organizations

Research & Development (19)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Shanghai YingLi Pharmaceutical Co. Ltd.For profit141142017
China Academy of Chinese Medical SciencesAcademic/Hospital5522023
Chinese Academy of Medical SciencesAcademic/Hospital5322019
Sun Yat-Sen UniversityAcademic/Hospital5322020
Jiao Tong UniversityAcademic/Hospital2212022
Nanjing Medical UniversityAcademic/Hospital2112023
Xiamen UniversityAcademic/Hospital2212023
Capital Medical UniversityAcademic/Hospital1112024
Dalian Medical UniversityAcademic/Hospital1112024
Fujian Medical UniversityAcademic/Hospital1012023
Fujian Provincial HospitalAcademic/Hospital1012023
Henan Medical UniversityAcademic/Hospital1112024
Hengrui Therapeutics, Inc.For profit1112025
Huizhou People's Central HospitalAcademic/Hospital1012023
Jieyang People's HospitalAcademic/Hospital1012023
Jinlin UniversityAcademic/Hospital1112024
Peking UniversityAcademic/Hospital1112023
Shanxi Medical UniversityAcademic/Hospital1012023
University of Texas at HoustonAcademic/Hospital1012022
19 organizations
Page 1 / 1